New FDA Drug Approval Pathway Aims to Promote, Ease Enrichment Trials

The FDA is considering a new drug approval pathway intended to boost development of treatments targeting small subgroups of patients with serious or life-threatening conditions. The pathway would establish a new, speedier process for studying a new drug or biological product in a smaller subpopulation of patients with more serious manifestations of a disease.
Drug Industry Daily